Long-term effect on body composition and metabolic parameters after treatment with recombinant human growth hormone (r-hGH) in HIV-1 infected patients with lipodystrophy

Autor:	Frank D. Goebel, Thomas Lutz, Johannes Eisen, Volkmar Jacobi, Schlomo Staszewski, Markus Bickel, S Klauke, Stephan Zangos, Catherine M. Crespi, Gabi Knecht
Rok vydání:	2008
Předmět:	Adult Male Microbiology (medical) medicine.medical_specialty Adolescent Adipose tissue HIV Infections Pilot Projects Intra-Abdominal Fat Gastroenterology law.invention Randomized controlled trial law Antiretroviral Therapy Highly Active Immunopathology Internal medicine Body Fat Distribution Humans Medicine Prospective Studies Sida Prospective cohort study General Immunology and Microbiology biology Human Growth Hormone business.industry Maintenance dose HIV-Associated Lipodystrophy Syndrome General Medicine Middle Aged medicine.disease biology.organism_classification Infectious Diseases medicine.anatomical_structure Endocrinology HIV-1 Abdomen Female Lipodystrophy business
Zdroj:	Scandinavian Journal of Infectious Diseases. 40:36-39
ISSN:	1651-1980 0036-5548
Popis:	Several studies have shown reduction of visceral adipose tissue (VAT) using recombinant human growth hormone (r-hGH) in HIV-1+ patients, but whether these effects are maintained after the end of treatment is unknown. In a prospective, randomized study we previously studied the effects of r-hGH 4 mg daily vs 3 times/week over 12 weeks, followed by a 2 mg daily maintenance dose for an additional 12 weeks. T1 weighted MRI flash sequences were performed of the face, abdomen and at mid-thigh level (MTF) at baseline, week 12, week 24 and at follow-up. Of 20 subjects who completed the 24-week study, follow-up is available for 16 patients (15 male, mean age 44.8 y, mean duration of HIV infection 13.5 y). After a median time of follow-up of 9 months, VAT remained overall 18% below baseline level (p =0.005). MTF was significantly reduced by 12% compared to its baseline level (p =0.03). Fasting glucose levels significantly improved by 21% compared to baseline (p =0.006). These results suggest that the achieved reduction of VAT using r-hGH in lipodystrophic HIV+ patients is in part maintained after a median follow-up of 9 months.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24459bdc54f4f733f01ee1ac430fc2fd https://doi.org/10.1080/00365540701487955 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.